Autism Research Strategy Stalls as Science Races Ahead

On the same day that a groundbreaking study in Science revealed critical advances in autism research—a comprehensive mapping of over 1,800 protein-protein interactions linked to 100 autism risk genes,投射出新的治疗开发路径—the federal Interagency Autism Coordinating Committee (IACC) convened for its second meeting and focused on outdated ideas that science has already moved beyond.

The contrast was stark: while scientists leveraged new data to highlight how diverse genetic mutations converge on shared biological pathways, committee members shared personal anecdotes and supported hypotheses, including the long-disproven claim that vaccines cause autism, which decades of research have thoroughly debunked.

The IACC approved a strategic plan that directs limited federal funding toward scientifically unsupported priorities, despite autism research progressing at an unprecedented pace—from identifying genetic risk factors to translating discoveries into genetic therapies. At a pivotal moment, the nation’s autism strategy should be forward-looking, not anchored in the past.

The new plan fails to reflect current science. Over the past decade, genetic research has yielded significant progress: hundreds of genes linked to autism, with specific genetic variants identified in approximately 20% of individuals. Innovative therapies like antisense oligonucleotides (ASOs) and CRISPR editing are showing promise in clinical trials for monogenic autism, such as SCN2A and UBE3A cases, where patients have experienced meaningful outcomes like speech recovery and seizure reduction.

However, the draft plan downplays these breakthroughs, emphasizing neurodevelopmental regression—which affects only about 30% of autistic individuals—over genetics and brain biology. It proposes extensive new research into potential causes like immune or metabolic issues, but lacks focus on regression as a manifestation of underlying genetics, contrary to contemporary science.

The committee’s framing appears to justify reopening decades-old questions about vaccines, ignoring robust studies. Additionally, despite thousands of public comments urging updates, the IACC chair blocked efforts to delay voting until all feedback was reviewed, prioritizing already-considered hypotheses over scientific evidence.

Critics argue that while public input is vital, a scientific strategy cannot merely tally popular ideas. Previous IACC committees appropriately weighed community voices against data, rejecting vaccine theories due to lack of evidence—a standard this plan fails to uphold.

The autism community urgently needs advancements grounded in evidence, and scientists are poised to deliver. The IACC must lead by encouraging integration of rigorous research with community needs, rather than revisiting settled questions at the expense of transformative discoveries that could improve lives. Autism science is advancing; our strategy should follow suit.

Source link